Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Receivables data on record, last reported at $194000.0 in Q2 2025.

  • For Q2 2025, Receivables fell 72.29% year-over-year to $194000.0; the TTM value through Jun 2025 reached $194000.0, down 72.29%, while the annual FY2024 figure was $318000.0, 6.71% up from the prior year.
  • Receivables reached $194000.0 in Q2 2025 per ACRS's latest filing, down from $250000.0 in the prior quarter.
  • Across five years, Receivables topped out at $963000.0 in Q2 2021 and bottomed at $194000.0 in Q2 2025.
  • Average Receivables over 5 years is $530444.4, with a median of $540500.0 recorded in 2022.
  • Peak YoY movement for Receivables: surged 62.41% in 2024, then plummeted 72.29% in 2025.
  • A 5-year view of Receivables shows it stood at $647000.0 in 2021, then decreased by 25.19% to $484000.0 in 2022, then plummeted by 38.43% to $298000.0 in 2023, then increased by 6.71% to $318000.0 in 2024, then plummeted by 38.99% to $194000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $194000.0 in Q2 2025, $250000.0 in Q1 2025, and $318000.0 in Q4 2024.